Skip to content

Managing Young People With ADHD in Primary Care Study

Managing Young People With Attention Deficit Hyperactivity Disorder in Primary Care (MAP) Study: Mapping Current Practice and Co-producing Guidance to Improve Healthcare in an Underserved Population

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05518435
Acronym
MAP
Enrollment
816
Registered
2022-08-26
Start date
2022-09-28
Completion date
2024-03-31
Last updated
2024-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHD

Keywords

Young adult, Service provision

Brief summary

Background: Attention deficit hyperactivity disorder (ADHD) is the most common childhood neurodevelopmental disorder. It affects around 5% of children and adolescents, and up to 40% continue to experience symptoms into adulthood. Primary care practitioners (e.g., general practitioners (GPs), nurses, link workers, clinical pharmacists) play an important role in the healthcare of young people (YP) with ADHD, particularly due to long waiting times in adult mental health services, and patchy provision of specialist services. However, many practitioners feel unsure about how to support YP at this vulnerable stage in their lives. Practitioners report concerns about prescribing ADHD medication and a desire for more guidance. Currently, little is known about how YP with ADHD are supported in primary care, the strengths and weakness of existing care pathways, and how care can be improved. Aims: To provide an evidence-base by mapping current services, and co-produce guidance to improve and better co-ordinate primary care for YP aged 16-25 with ADHD. Methods: Three interlinked studies. A mapping study including a national survey of stakeholders to map patient pathways, prescribing practice, shared-care arrangements, and practitioner roles. A qualitative study including semi-structured interviews with YP and practitioners, to gain insight into experiences of 'what works' and 'what is needed'. Workshops to co-develop a map of patient pathways, key messages, and clinical guidance. Patient Involvement: This research has been developed in response to identified gaps in services, and requests from people with ADHD. The team includes young people with ADHD whose input will help ensure the research is sensitive and relevant, and an academic GP to ensure identified solutions are deliverable within primary care settings. Impact: The expected impact of this research is improvement of the quality and experience of care for YP with ADHD. Also, to improve experiences of primary care providers facing difficulties managing ADHD.

Detailed description

This research aims to map current services and co-create evidence-based guidance to improve and better co-ordinate primary care for young people aged 16-25 years with ADHD. OBJECTIVES The objectives of this research are to: 1. Develop a national map and overview of current primary care pathways and prescribing practice in the management of young people with ADHD 2. Explore: 1. Primary care providers and related organisations' needs for information resources and prescribing support in their roles managing care for young people with ADHD 2. The expectations and needs of young people aged 16-25 regarding primary care ADHD support, information, and management 3. Co-produce evidence informed guidance to better co-ordinate primary care for young people with ADHD, based on discussions around findings from objectives 1, 2a and 2b OUTCOMES The outcomes of this research will be shaped by close work with professionals and members of the community, via the practice and policy research advisory group (P-RAG) and young person and parent/carer research advisory group (Y-RAG) groups, to ensure their relevance and utility. Anticipated outcomes include: 1. National overview of primary care provision for young people with ADHD across England, including: 1. Geographic map, showing variation in provision by NHS region or appropriate organisational boundaries 2. Summary of existing care pathways for the management of young people with ADHD in primary care, including exemplars of best practice 2. Qualitative summary of the perspectives of people involved in delivering and in need of care, on the management of ADHD in primary care including: 1. Health professionals' needs for information resources and prescribing support 2. Young people with ADHD and their parent/carers' needs for information resources, healthcare, and support with self-management 3. Co-produced guidance on how to better co-ordinate and design primary care for young people aged 16-25 with ADHD. STUDY DESIGN and METHODS Overview: This mixed methods study consists of three work packages. Each WP involves data collection/creation working with the following stakeholder groups. * Patients, with a focus on young people (aged 16-25) with ADHD, and their parent/carers * Health professionals, with a focus on those in primary care (including general practitioners (GPs), specialist nurses, mental health practitioners, and clinical pharmacists) * Commissioners/providers of NHS healthcare for people with ADHD

Interventions

The MAP study involves mapping current practice (WP1), exploring current experiences (WP2), and co-creating guidance based on existing evidence (WP3).

Sponsors

University of Exeter
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Participants will include people aged 16 or over with lived experience of ADHD (and their parent/carers), health professionals with a focus on primary care (such as GPs, nurses, mental health practitioners, and clinical pharmacists), and primary care commissioners/providers. Sampling, recruitment strategies, and eligibility criteria, vary slightly between work packages, as outlined below. WP1 SURVEY Inclusion Criteria: Self-identifies as * Being at least one of the following: * A person aged 16 or over with lived experience of ADHD, or parent/carer of a person with ADHD * Health professional (person working in any role that provides healthcare services, include NHS, voluntary and private services, clinical, managerial, leadership and administrative roles) * Commissioner/provider of National Health Service (NHS) healthcare services (e.g., member of clinical commissioning group, primary care network (PCN), integrated care system (ICS), or another NHS organisation) * Currently resident, working, or studying in England

Exclusion criteria

* Does not identify as a person aged 16 or over with lived experience of ADHD, a health professional, or a commissioner/provider of NHS health services * Not currently resident, working, or studying in England WP2 QUALITATIVE STUDY Inclusion Criteria: * One of the following: * Young person aged 16-25 with lived experience of ADHD, or a parent/carer of a young person with ADHD * Health professional (person that provides healthcare services with a focus on primary care, including clinical, managerial, leadership and administrative roles) * Commissioner/provider of healthcare services (e.g., member of clinical commissioning group, PCN, ICS, NHS, or another organisation) * Currently resident or working in England * Currently resident or working close to one of the qualitative study sites identified following WP1, where 'close to' means located within the same geographic locality (to be decided based on findings from WP1)

Design outcomes

Primary

MeasureTime frameDescription
WP1: Reports of the prescribing of adult ADHD medication, by primary care practices in EnglandAt time of completing surveyWP1 (national survey) will report on prescribing of ADHD medication by primary care practices in England. Outcome data will be communicated as a summary total of 'yes' / 'no' survey responses, and analysed by the geographic location of practices, as well as the type of respondent reporting this practice (e.g., person with ADHD, clinician, or commissioner)

Secondary

MeasureTime frameDescription
WP1: Reports of shared care agreements being in place for prescribing of adult ADHD medication, by local primary care practices (in England)At time of completing surveyWP1 (national survey) will report on the presence of shared care agreements for prescribing of ADHD medication by primary care practices in England. Outcome data will be communicated as a summary total of 'yes' / 'no' survey responses, and analysed by the geographic location of practices, as well as the type of respondent reporting this practice (e.g., person with ADHD, clinician, or commissioner)
WP1: Reports of mental health support being in place for patients with adult ADHD medication, by local primary care practices (in England)At time of completing surveyWP1 (national survey) will report on the presence of shared care agreements for prescribing of ADHD medication by primary care practices in England. Outcome data will be communicated as a summary total of 'yes' / 'no' survey responses, and analysed by the geographic location of practices, as well as the type of respondent reporting this practice (e.g., person with ADHD, clinician, or commissioner)
WP2: Qualitative summary of the perspectives of people involved in delivering and in need of care, on the management of ADHD in primary care medication, by local primary care practices (in England)At time of interviewWP2 (qualitative study) will report on experiences of primary care provision for young people with ADHD across England, from the perspectives of health professionals and young people with ADHD. Topics covered will include, prescribing practice, shared care agreements, and information provision.

Other

MeasureTime frameDescription
WP3: Co-produced guidance on how to better co-ordinate and design primary care for young people aged 16-25 with ADHD.At time of co-production workshopsWP3 (co-production study) will deliver an output in the form of co-produced guidance on how to better co-ordinate and design primary care for young people aged 16-25 with ADHD.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 9, 2026